Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × 30 days × Clear all

NCT03047213 2026-03-18

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2 Active not recruiting

17 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03237780 2026-03-18

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03375307 2026-03-18

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03866382 2026-03-18

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04164082 2026-03-18

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07061964 2026-03-18

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03652298 2026-03-13

NeuroPrevPTSD

Phase 2 Terminated

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Prostatic Neoplasms, Stress Disorders, Post-Traumatic, Colorectal Neoplasms

NCT04640623 2026-03-13

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07050771 2026-03-12

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Phase 2 Recruiting

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2 Active not recruiting

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT06528990 2026-03-05

Telehealth Intervention for Ostomy Self-Management

Phase 2 Recruiting

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Colorectal Neoplasms

NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Phase 2 Active not recruiting

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

NCT06760819 2026-03-04

panSOHO

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT04138628 2026-03-02

TOMBOLA

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT05581589 2026-02-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2 Recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03520491 2026-02-17

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07414992 2026-02-17

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms